Could Illumina Inc (NASDAQ:ILMN) See a Reversal After More Sellers Came In?

Illumina, Inc. (NASDAQ:ILMN) Logo

Investors sentiment decreased to 1.12 in 2019 Q2. Its down 0.21, from 1.33 in 2019Q1. It worsened, as 40 investors sold Illumina, Inc. shares while 229 reduced holdings. 81 funds opened positions while 220 raised stakes. 129.16 million shares or 24.32% less from 170.65 million shares in 2019Q1 were reported.
Private Advisor Gru Limited Com has 6,956 shares. Copper Rock Cap Limited Liability stated it has 29,576 shares or 0.8% of all its holdings. Verition Fund Lc holds 0.57% or 54,595 shares in its portfolio. Advisor Ptnrs Limited Co has 0.16% invested in Illumina, Inc. (NASDAQ:ILMN). Commonwealth Bank Of accumulated 243 shares. Castleark Limited holds 101,092 shares. Lockheed Martin Inv Mgmt reported 42,190 shares. Stone Ridge Asset Mgmt Limited Liability Company holds 2,088 shares. 11.41 million are owned by Vanguard Gru. Wafra stated it has 33,712 shares or 0.42% of all its holdings. 20,080 were reported by Marshall Wace Limited Liability Partnership. 6,014 are held by Qs Invsts Ltd Liability. The New York-based National Asset Incorporated has invested 0.06% in Illumina, Inc. (NASDAQ:ILMN). Pictet Cie (Europe) Sa has 700 shares for 0.04% of their portfolio. Mariner Limited Liability Corporation stated it has 0.02% in Illumina, Inc. (NASDAQ:ILMN).

The stock of Illumina Inc (NASDAQ:ILMN) registered an increase of 1.34% in short interest. ILMN’s total short interest was 2.53M shares in September as published by FINRA. Its up 1.34% from 2.50M shares, reported previously. With 940,800 shares average volume, it will take short sellers 3 days to cover their ILMN’s short positions.

The stock increased 1.43% or $4.25 during the last trading session, reaching $301.77. About 854,657 shares traded. Illumina, Inc. (NASDAQ:ILMN) has risen 3.51% since September 13, 2018 and is uptrending. It has outperformed by 3.51% the S&P500.

Illumina, Inc. provides sequencing and array solutions for genetic analysis. The company has market cap of $44.36 billion. The companyÂ’s sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It has a 47.9 P/E ratio. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array.

Illumina, Inc. (NASDAQ:ILMN) Ratings Coverage

Among 3 analysts covering Illumina (NASDAQ:ILMN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Illumina has $35500 highest and $30000 lowest target. $334.33’s average target is 10.79% above currents $301.77 stock price. Illumina had 6 analyst reports since April 16, 2019 according to SRatingsIntel. UBS maintained Illumina, Inc. (NASDAQ:ILMN) on Tuesday, July 30 with “Buy” rating. The firm earned “Hold” rating on Tuesday, July 30 by Canaccord Genuity. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Overweight” rating by Piper Jaffray on Tuesday, July 30.

More notable recent Illumina, Inc. (NASDAQ:ILMN) news were published by: which released: “If You Had Bought Illumina (NASDAQ:ILMN) Shares Three Years Ago You’d Have Made 67% – Yahoo Finance” on August 19, 2019, also with their article: “Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know – Nasdaq” published on September 04, 2019, published: “Illumina is Now Oversold (ILMN) – Nasdaq” on September 09, 2019. More interesting news about Illumina, Inc. (NASDAQ:ILMN) were released by: and their article: “4 5-Star Companies to Consider as Dow Eclipses 27,000 – Yahoo Finance” published on September 12, 2019 as well as‘s news article titled: “Stocks – Market Surges on Apple, Tech and Boeing Gains – Yahoo Finance” with publication date: September 11, 2019.

Illumina, Inc. (NASDAQ:ILMN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.